Cytokinetics to Present at Healthcare Conferences in March
February 24 2015 - 4:00PM
South San Francisco, CA, February 24, 2015 -
Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that
Robert I. Blum, President and Chief Executive Officer, is scheduled
to present a corporate update at the following healthcare
conferences:
Cowen and Company 35th Annual
Health Care Conference
Date: Tuesday, March 3, 2015
Time: 11:20 AM Eastern Time
Location: Boston Marriott Copley Place Hotel, Boston, MA
27th Annual ROTH
Conference
Date: Monday, March 9, 2015
Time: 8:30 AM Pacific Time
Location: Ritz-Carlton, Laguna Nigel, Dana Point, CA
Interested parties may access the
live audio of this presentation by visiting the Investor Relations
section of the Cytokinetics website at www.cytokinetics.com. The
webcast replay of the presentation will be archived on the
Presentations page within the Investor Relations section of
Cytokinetics' website for two weeks following the completion of the
event.
About Cytokinetics
Cytokinetics is a clinical-stage
biopharmaceutical company focused on the discovery and development
of novel small molecule therapeutics that modulate muscle function
for the potential treatment of serious diseases and medical
conditions. Cytokinetics is developing tirasemtiv, a fast skeletal muscle activator, as a
potential treatment for amyotrophic lateral sclerosis (ALS).
Tirasemtiv has been granted orphan drug
designation and fast track status by the U.S. Food and Drug
Administration and orphan medicinal product designation by the
European Medicines Agency for the potential treatment of ALS.
Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a cardiac muscle activator, for the
potential treatment of heart failure. Cytokinetics is
collaborating with Astellas Pharma Inc. to develop CK-2127107, a
skeletal muscle activator, for spinal muscular atrophy. Amgen holds
an exclusive license worldwide to develop and commercialize
omecamtiv mecarbil and Astellas holds an
exclusive license worldwide to develop and commercialize
CK-2127107. Both licenses are subject to Cytokinetics'
specified development and commercialization participation
rights. All of these drug candidates have arisen from
Cytokinetics' muscle biology focused research activities and are
directed towards the cytoskeleton. The cytoskeleton is a complex
biological infrastructure that plays a fundamental role within
every human cell. Additional information about Cytokinetics can be
obtained at http://www.cytokinetics.com/.
This press
release contains forward-looking statements for purposes of the
Private Securities Litigation Reform Act of 1995 (the "Act").
Cytokinetics disclaims any intent or obligation to update these
forward-looking statements, and claims the protection of the Act's
safe harbor for forward-looking statements. Examples of such
statements include, but are not limited to, statements relating to
planned presentations, and the properties and potential benefits of
Cytokinetics' drug candidates and potential drug candidates. Such
statements are based on management's current expectations, but
actual results may differ materially due to various risks and
uncertainties, including, but not limited to, potential
difficulties or delays in the development, testing, regulatory
approval and production of Cytokinetics' drug candidates and
potential drug candidates that could slow or prevent clinical
development or product approval, including risks that current and
past results of clinical trials or preclinical studies may not be
indicative of future clinical trials results and that Cytokinetics'
drug candidates and potential drug candidates may have unexpected
adverse side effects or inadequate therapeutic efficacy. For
further information regarding these and other risks related to
Cytokinetics' business, investors should consult Cytokinetics'
filings with the Securities and Exchange Commission.
Contacts:
Cytokinetics,
Incorporated:
Joanna L.
Goldstein
Manager, Investor Relations & Corporate
Communications
(650) 624-3000
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Cytokinetics, Inc. via Globenewswire
HUG#1896948
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Apr 2023 to Apr 2024